Pre-made Gavilimomab benchmark antibody (Whole mAb, anti-BSG therapeutic antibody, Anti-5F7/CD147/EMMPRIN/EMPRIN/HAb18G/OK/TCSF Antibody) for drug discovery and mechanism of action (MOA) research

Anti-BSG therapeutic antibody (Pre-made Gavilimomab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147.[1] Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.[2]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-853-1mg	1mg	3090
GMP-Bios-INN-853-10mg	10mg	Inquiry
GMP-Bios-INN-853-100mg	100mg	Inquiry
GMP-Bios-INN-853-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Gavilimomab Biosimilar, Whole Mab, Anti-Bsg Antibody: Anti-5F7/CD147/EMMPRIN/EMPRIN/HAb18G/OK/TCSF therapeutic antibody
INN Name	Gavilimomab
Target	BSG
Format	Whole mAb
Derivation	Mus musculus
Species Reactivity	human
CH1 Isotype	IgM - nd
VD LC	IgM - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Abgenix (Fremont CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0